Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

The conversation discusses using topical dutasteride with a dermapen for hair loss treatment. The user is deciding between liposomal and mesosomal formulations for this purpose.

The conversation is about hair loss treatments, specifically asking for updates on verteporfin research following promising results. No specific treatments were discussed in the provided text.

Diffuse thinning is often due to androgenetic alopecia, and DHT blockers like finasteride are recommended. Treatments mentioned include minoxidil, finasteride, dutasteride, and RU58841, with emphasis on starting early and using a holistic approach.

PP405 from Everychem is likely fake and potentially harmful, with concerns about its stability and the risk of using the wrong MPC inhibitor, which could damage hair follicles. The real PP405 was studied under strict conditions, and DIY attempts are discouraged due to unknown formulation and quality control.

The user is treating hair loss with dermarolling, a laser helmet, scalp massages, and Nizoral. They stopped using minoxidil and finasteride and are considering pumpkin seed oil and sulforaphane.

PP405 shows promise in stimulating new terminal hair growth by activating dormant follicles, with no systemic adverse effects observed in a short-term trial. However, long-term efficacy remains unproven, and further trials are needed to confirm its potential as a hair loss treatment.

Blocking DHT may slow down aging and improve skin, with users reporting positive effects from finasteride. Minoxidil and RU58841 are also mentioned as treatments.

The user is using topical finasteride, Bioscalin, Omega 3, and hair filler therapy for hair loss. There is some progress noted, but varying photo angles and lighting make it hard to assess fully.

Keratin fusion bonds are discussed as an alternative to clip-on hair patches for men with diffused thinning. The conversation explores different styling options for hair loss.

A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

The user plans to use a combination of tretinoin, topical minoxidil, and topical finasteride for hair loss treatment. They seek advice on application order, timing, and tretinoin dosage.

The conversation discusses using natural DHT blockers like saw palmetto, beta sitosterol, pumpkin seed oil, pygeum africanum bark, and nettle root as alternatives to finasteride for hair loss, with mixed opinions on their effectiveness. Some users report minimal improvement with natural options and better results with finasteride or dutasteride, despite concerns about potential side effects.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

BPC-157 may promote hair growth by increasing angiogenesis, similar to how Minoxidil works, though no direct research confirms this yet. Users report combining BPC-157 with Minoxidil and finasteride for better results, but concerns about long-term safety exist.

Hair loss discussion mentions treatments Minoxidil, Finasteride, and RU58841. Verteporfin shows promise for scar/regrowth after 84 days.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

Treatments for hair loss, including microneedling, finasteride, minoxidil, dutasteride, RU-58841, pyrilutamide, pumpkin seed oil, rosemary water, orchiectomy, and estrogen.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A topical treatment called 1961, containing multiple products, is discussed for its compatibility with finasteride. It is suggested that 1961 does not negatively affect finasteride's effectiveness and may even enhance its absorption.

The conversation is about people with advanced hair loss (Norwood 6 or 7) who have seen significant hair regrowth using treatments like finasteride, minoxidil, microneedling, and RU58841. Nine cases were collected to motivate others to try these treatments despite advanced hair loss.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

New hair loss treatments, including Breezula, VDPHL01, and PP405, are nearing Phase 3 trials, offering hope for effective solutions. Current treatments like finasteride and minoxidil remain effective, but early intervention is crucial.

The conversation discusses the potential of verteporfin in treating hair loss, with some users reporting positive results and speculating that it could lead to a cure for baldness. Others are skeptical, and there's a debate on the effectiveness of verteporfin for regrowing hair and reducing transplant scars.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

User experienced slow gains with topical fin+min, switched to topical dut+min, and considered adding Eucapil. Another user suggested DUT may be less effective topically due to high molar mass and mentioned Fluridil as a weak anti-androgen that could help.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.